Seeing congestion before it speaks: inferior vena cava-guided management in heart failure
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
This editorial refers to ‘Long-term safety and performance of an implantable IVC sensor for congestion-guided management in heart failure: 12-month results from the FUTURE-HF trial portfolio, by K. Damman et al., https://doi.org/10.1093/ejhf/xuag080. Just because you can’t see anything, doesn´t mean you should shut your eyes. Ray Charles Heart failure (HF) remains defined by congestion. Despite advances in disease-modifying therapies, recurrent decompensation continues to drive hospitalization, impaired quality of life, and escalating healthcare costs. Clinical congestion is frequently detected late, when symptoms have already intensified and hospital admission becomes likely. Traditional tools, body weight, physical examination, and even natriuretic peptides lack sensitivity for early detection of intravascular volume expansion and venous congestion.1,2 The search for reliable, actionable, and scalable congestion monitoring remains one of the most pressing unmet needs in HF management. In this issue of the European Journal of Heart Failure, Dammanet al.3 report the 12-month results of the FUTURE-HF trial portfolio, evaluating long-term safety and performance of an implantable inferior vena cava (IVC) sensor to guide congestion management. Their study offers an important and timely contribution to the evolving landscape of remote physiological monitoring in HF.
Fields of Study & Subjects
Heart Failure Treatment and Management
Cardiac pacing and defibrillation studies
Mechanical Circulatory Support Devices
Publication details
- Journal / source
- European Journal of Heart Failure
- Pages
- xuag052
- Publication date
- 1 April 2026
- Language
- EN